Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 191

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 191
---
 outstanding:Basic and diluted90.6 82.8 80.6 

See accompanying notes to consolidated financial statements.

78

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Consolidated Statements of Comprehensive Loss

(in millions)

Years Ended December 31,202420232022Net loss attributable to Myriad Genetics, Inc. stockholders$(127.3)$(263.3)$(112.0)Change in unrealized loss on available-for-sale debt securities, net of tax0.1 1.2 (2.5)Change in foreign currency translation adjustment, net of tax(3.0)2.1 (1.3)Reclassification adjustments for losses included in net loss, net of tax— 1.5 — Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax5.8 0.4 — Comprehensive loss$(124.4)$(258.1)$(115.8)

See accompanying notes to consolidated financial statements.

79

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Consolidated Statements of Stockholders’ Equity

(in millions)

CommonstockAdditionalpaid-incapitalAccumulatedothercomprehensive lossAccumulateddeficitMyriadGenetics, Inc.Stockholders’equityBALANCES AT DECEMBER 31, 2021$0.8 $1,226.3 $(5.1)$(254.2)$967.8 Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— (4.3)— — (4.3)Stock-based compensation expense— 38.1 — — 38.1 Net loss— — — (112.0)(112.0)Other comprehensive loss, net of tax— — (3.8)— (3.8)BALANCES AT DECEMBER 31, 2022$0.8 $1,260.1 $(8.9)$(366.2)$885.8 Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— (2.8)— — (2.8)Issuance of common stock for public offering, net0.1 117.5